70-gene signature cost effective in guiding breast cancer therapy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2020 Category: Drugs & Pharmacology Source Type: news

How the COVID-19 Pandemic Has Changed Cancer Care, In 4 Charts
Before the pandemic, about 1,000 new patients came to Boston’s Dana-Farber Cancer Institute for treatment consultations each week. When COVID-19 hit Massachusetts this spring, the number of new consultations fell by half and the hospital moved as many appointments as possible online. Now, with daily case counts relatively low in the area, the hospital is back to scheduling about 800 consultations per week, using a mixture of telemedicine and in-person appointments, says associate chief medical officer Dr. Andrew Wagner—but that still means about 200 cancer patients per week are not getting the treatment consult...
Source: TIME: Health - August 28, 2020 Category: Consumer Health News Authors: Jamie Ducharme and Emily Barone Tags: Uncategorized COVID-19 Source Type: news

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test
Basel, 28 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne ®Liquid CDx, Foundation Medicine’s comprehensive pan-tumour liquid biopsy test for patients with solid tumours. FoundationOne Liquid CDx is a comprehensive genomic profiling (CGP) test that analyses more than 300 cancer-related genes and multiple genomic signatures to optimise patient care. Cance r is a disease of the genome, driven by genetic mutations within a tumour’s DNA. CGP is used to identify these unique mutations to determine how a tumour behaves and...
Source: Roche Investor Update - August 28, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test
Basel, 28 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne ®Liquid CDx, Foundation Medicine’s comprehensive pan-tumour liquid biopsy test for patients with solid tumours. FoundationOne Liquid CDx is a comprehensive genomic profiling (CGP) test that analyses more than 300 cancer-related genes and multiple genomic signatures to optimise patient care. Cance r is a disease of the genome, driven by genetic mutations within a tumour’s DNA. CGP is used to identify these unique mutations to determine how a tumour behaves and...
Source: Roche Media News - August 28, 2020 Category: Pharmaceuticals Source Type: news

Bucks County biopharm firm's stock plunges after key product fails in late-stage testing
Onconova Therapeutics' stock price plummeted by more than 70% Monday morning after the company announced disappointing results from late-stage testing of its lead new drug candidate. The Newtown biopharmaceutical company said results from its phase-III clinical trial showed its experimental cancer therapy, IV rigosertib, did not meet its primary endpoint of improved survival rates for patients. The disclosure sent Onconova's (NASDAQ: ONTX) stock price down from $1.01 per shar e to 30 cents. The… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 24, 2020 Category: Biotechnology Authors: John George Source Type: news

p16INK4a Expression Increased in Young Cancer Survivors
MONDAY, Aug. 24, 2020 -- Pediatric and young adult cancer survivors, frail versus robust survivors, and newly diagnosed pediatric patients after cancer therapy have increased expression of p16INK4a, corresponding with age acceleration, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 24, 2020 Category: Pharmaceuticals Source Type: news

In one cancer therapy, two halves are safer than a whole
(Ohio State University) Splitting one type of cancer drug in half and delivering the pieces separately to cancer cells could reduce life-threatening side effects and protect healthy, non-cancerous cells, a new study suggests. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 24, 2020 Category: Cancer & Oncology Source Type: news

A metabolic enzyme as a potential new target for cancer immune therapies
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) The metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promotes the spread of tumor cells and suppresses the immune system. This was discovered by scientists at the German Cancer Research Center (DKFZ) and the Berlin Institute of Health (BIH). The enzyme that activates the dioxin receptor is produced in large quantities by tumor cells. In the future, substances that inhibit IL4I1 could open up new opportunities for cancer therapy. The scientists have now published their results in the journal Cell. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 20, 2020 Category: International Medicine & Public Health Source Type: news

New 'molecular computers' find the right cells
(University of Washington Health Sciences/UW Medicine) New nanoscale devices, made of synthetic proteins, have been designed to target a therapeutic agent only to cells with a specific, predetermined combinations of cell surface markers. They operate on their own and search out cells they were programmed to find. The hope is that they might guide CAR T cancer therapy, and other treatments where precision is critical, through a sort of molecular beacon. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 20, 2020 Category: Cancer & Oncology Source Type: news

Intestinal bacteriophage alters effects of cancer therapies in mice
(American Association for the Advancement of Science) Enterococcus, a genus that includes common commensal bacteria found in the gut, harbors a bacteriophage that influences the effects of various cancer immunotherapies in ways that may be clinically relevant, researchers working in mice report. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 20, 2020 Category: Cancer & Oncology Source Type: news

Targeting STING for cancer therapy
(Source: ScienceNOW)
Source: ScienceNOW - August 20, 2020 Category: Science Authors: Kelly, P. N. Tags: Medicine, Diseases twis Source Type: news

New tools catch and release molecules at the flip of a light switch
(Princeton University, Engineering School) A Princeton team has developed a class of light-switchable, highly adaptable molecular tools with new capabilities to control cellular activities. The antibody-like proteins, called OptoBinders, have potential applications including protein purification, the improved production of biofuels, and new types of targeted cancer therapies. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 13, 2020 Category: Biology Source Type: news

New approach for calculating radiation dosimetry allows for individualized therapy
(Society of Nuclear Medicine and Molecular Imaging) Researchers have developed a simplified process that could enhance personalization of cancer therapy based on a single nuclear medicine scan. The novel method uses a follow-up single photon emission computed tomography/computed tomography (SPECT/CT) scan to obtain reliable radiation dose estimates to tumors and at-risk organs. The study is published in The Journal of Nuclear Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 11, 2020 Category: Cancer & Oncology Source Type: news

New guidelines for managing mucositis now available
(University of Rochester Medical Center) New guidelines are now available to provide healthcare professionals with better tools to manage mucositis, a common and often debilitating complication of cancer therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 11, 2020 Category: Cancer & Oncology Source Type: news

Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients
This observational study of cancer patients diagnosed with Covid-19 (n=890; 218 in the UK) found no evidence that receipt of anti-cancer therapy (chemotherapy, targeted therapy, endocrine therapy and immunotherapy) was associated with mortality. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 10, 2020 Category: Consumer Health News Source Type: news

Most Gynecologic Cancer Therapy Not Tied to Higher COVID - 19 Risk
Only recent immunotherapy use linked to death due to COVID - 19 in gynecologic oncology patients (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Gynecology, Infections, Oncology, Pathology, Pharmacy, Radiology, Surgery, Critical Care, Journal, Source Type: news

Most Gynecologic Cancer Therapy Not Tied to Higher COVID-19 Risk
THURSDAY, July 30, 2020 -- For gynecologic oncology patients with COVID-19, the case fatality rate is 14.0 percent, and chemotherapy and recent major surgery do not predict COVID-19 severity or mortality, according to a study published online July... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 30, 2020 Category: Pharmaceuticals Source Type: news

Phosphoprotein biomarkers to guide cancer therapy are identified
(University of Alabama at Birmingham) Researchers led by James Bibb, Ph.D., professor of surgery at the University of Alabama at Birmingham, suggest using a broader lens of post-translational modification analysis to identify new biomarkers of cancer drivers that may allow a much more precise prediction of patient responses to treatments. In a study published in Proceedings of the National Academy of Sciences, they demonstrate this diagnostic alternative for neuroendocrine neoplasms driven by an aberrantly activated protein kinase called Cdk5. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 28, 2020 Category: International Medicine & Public Health Source Type: news

Genetic Differences by Ancestry and Prostate Cancer Therapies Genetic Differences by Ancestry and Prostate Cancer Therapies
Genetic differences in prostate tumors from African American men and European-American men are of no clinical significance, according to an analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Studies suggest a fasting diet could boost breast cancer therapy
(University of Southern California) A USC-led team of scientists has found that a fasting-mimicking diet combined with hormone therapy has the potential to help treat breast cancer, according to newly published animal studies and small clinical trials in humans. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 21, 2020 Category: International Medicine & Public Health Source Type: news

Arkansas Hospitals, Georgia Company to Bring New Cancer Therapy to Arkansas
Three Arkansas hospitals and Proton International LLC have signed a letter of intent to bring the state’s first proton therapy center to the University of Arkansas for Medical Sciences’ Radiation Oncology Center. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - July 16, 2020 Category: American Health Source Type: news

RaySearch, TAE Life Sciences partner on cancer therapy
Radiation therapy software developer RaySearch Laboratories has entered into...Read more on AuntMinnie.comRelated Reading: AI algorithm boosts Swedish clinic's workflow RaySearch unveils new RayStation release RaySearch, Varian partner to track radiation therapy RaySearch inks Australian contract Accuray, RaySearch treat 1st patients in Asia-Pacific (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 16, 2020 Category: Radiology Source Type: news

Tumor-initiating cells establish an IL-33-TGF-{beta} niche signaling loop to promote cancer progression
Targeting the cross-talk between tumor-initiating cells (TICs) and the niche microenvironment is an attractive avenue for cancer therapy. We show here, using a mouse model of squamous cell carcinoma, that TICs play a crucial role in creating a niche microenvironment that is required for tumor progression and drug resistance. Antioxidant activity in TICs, mediated by the transcription factor NRF2, facilitates the release of a nuclear cytokine, interleukin-33 (IL-33). This cytokine promotes differentiation of macrophages that express the high-affinity immunoglobulin E receptor FcRIα and are in close proximity to TICs. ...
Source: ScienceNOW - July 16, 2020 Category: Science Authors: Taniguchi, S., Elhance, A., Van Duzer, A., Kumar, S., Leitenberger, J. J., Oshimori, N. Tags: Cell Biology, Medicine, Diseases, Online Only r-articles Source Type: news

Infographic: How Immunotherapy Could Boost Stem-Like T Cells
Cancer therapies could potentially be more effective if their development took into account the cells that give rise to tumor-fighting cells. (Source: The Scientist)
Source: The Scientist - July 13, 2020 Category: Science Tags: Infographics Magazine Issue Source Type: news

Study Shows Benefits of Integrating Dermatology Into Oncology Study Shows Benefits of Integrating Dermatology Into Oncology
Incorporating skin toxicity protocols at a cancer center significantly increased the rate of prophylactic treatment for rashes resulting from cancer therapies.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 8, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

JNCCN study explores if insurance is keeping pace with trends in targeted cancer therapy
(National Comprehensive Cancer Network) New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN--Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or 'liquid biopsies.' The researchers found coverage rate rose from 0% to 38% in three years. The policies also increased in scope from 2017-2019, going from one cancer type to 12. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2020 Category: Cancer & Oncology Source Type: news

DNA repair discovery holds promise for precision cancer therapy
NIEHS and Canadian scientists discover that cancer cells with mutated BRCA1 and BRCA2 genes died when they lacked a protein called APE2. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - July 6, 2020 Category: Environmental Health Source Type: news

MIPT bioinformaticians find way to personalize drug prescription against stomach cancer
(Moscow Institute of Physics and Technology) Researchers from the Moscow Institute of Physics and Technology and their colleagues have developed the first technique for personalizing stomach cancer therapy based on RNA sequencing of tumor cells. The study, supported by the Russian Science Foundation, was published in Cold Spring Harbor Molecular Case Studies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 30, 2020 Category: Cancer & Oncology Source Type: news

Vitamin D may help prevent a common side effect of anti-cancer immunotherapy
(Wiley) New research published in CANCER indicates that taking vitamin D supplements may help prevent a potentially serious side effect of a revolutionary form of anti-cancer therapy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 22, 2020 Category: Biology Source Type: news

Roche ’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
      ·Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary endpoint of radiographic progression free survival (rPFS) in patients with PTEN loss tumoursBasel, 19 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCR...
Source: Roche Media News - June 19, 2020 Category: Pharmaceuticals Source Type: news

Cardiology Care Ups CV Monitoring, BP Control in Breast Cancer Cardiology Care Ups CV Monitoring, BP Control in Breast Cancer
A new study supports a broader role for cardiologists, beyond the current focus on cancer therapy-related cardiovascular complications.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 18, 2020 Category: Cancer & Oncology Tags: Cardiology News Source Type: news

Lilly's breast cancer drug succeeds in late-stage study
Eli Lilly and Co said on Tuesday that its breast cancer therapy Verzenio met the main goal of reducing the risk of it returning in the early stages in a late-stage study, sending its shares up 8.5% in pre-market trade. (Source: Reuters: Health)
Source: Reuters: Health - June 16, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Nanobiohybrids: A synergistic integration of bacteria and nanomaterials in cancer therapy
(Compuscript Ltd) Nanobiohybrids: A Synergistic Integration of Bacteria and Nanomaterials in Cancer Therapy- BIO Integration. Announcing a new article publication for BIO Integration journal. In this mini review article the authors Yuhao Chen, Meng Du, Jinsui Yu, Lang Rao, Xiaoyuan Chen and Zhiyi Chen from The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China and the National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD, USA consider nanobiohybrids in cancer therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 16, 2020 Category: International Medicine & Public Health Source Type: news

Exploring the potential of magnetic hyperthermia to kill cancer cells
In this study, Bulgarian researchers investigated the potential of mixed ferrite nanoparticles with the structural formula Me1?xZnxFe2O4 (Me = Co, Ni, Cu, Mn) for cancer therapy. Their results were published in The European Physical Journal B. Magnetic nanoparticles (MNPs) can be delivered close to tumor cells and activated using alternating magnetic fields. This new type... (Source: NaturalNews.com)
Source: NaturalNews.com - June 15, 2020 Category: Consumer Health News Source Type: news

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
(University of California - Irvine) A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2020 Category: International Medicine & Public Health Source Type: news

Study by NUI Galway researchers into DNA biology could impact future anti-cancer therapies
(National University of Ireland Galway) A study by the Centre for Chromosome Biology at NUI Galway, Ireland, in partnership with the University of Zurich, has uncovered new insights into how the replication of DNA occurs which can be applied to help develop novel cancer treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 9, 2020 Category: International Medicine & Public Health Source Type: news

Alpha Tau Medical Announces Successful Completion of New $26 Million Funding Round
TEL AVIV, Israel, June 4, 2020 -- (Healthcare Sales & Marketing Network) -- Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, is pleased to announce the closing of a Series B equity financing of $26 million. Inves... Devices, Oncology, Venture Capital Alpha Tau Medical, alpha-radiation, Alpha DaRT, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 4, 2020 Category: Pharmaceuticals Source Type: news

Sirtex Medical appoints Dr. Mark A. Turco as Global Chief Medical Officer and EVP of Research and Development
Industry veteran to lead Medical and Clinical Affairs to advance clinical trials and accelerate further development of cancer therapies WOBURN, Mass., June 3, 2020 -- (Healthcare Sales & Marketing Network) -- Sirtex Medical US Holdings, Inc. ("Sir... Devices, Oncology, Personnel Sirtex Medical, SIR-Spheres, liver cancer, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 3, 2020 Category: Pharmaceuticals Source Type: news

WPI-led research team shrinks breast cancer tumors in mice with targeted therapy
(Worcester Polytechnic Institute) A team of researchers led by Worcester Polytechnic Institute Provost Wole Soboyejo attached anti-cancer agents to the hormone LHRH to create drugs that targeted triple-negative breast cancer, which typically does not respond to conventional targeted cancer therapies. The researchers reported that the treatments reduced the size of tumors in mice with no signs of toxic side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2020 Category: Cancer & Oncology Source Type: news

Cancer drugs cause large cells that resist treatment; scientist aims to stop it
(University of Texas Health Science Center at San Antonio) Fueled by genetic changes due to cancer therapy itself, rogue cells may become very large with twice or quadruple the number of chromosomes found in healthy cells. Dr. Daruka Mahadevan of the Mays Cancer Center, home to UT Health San Antonio MD Anderson, seeks to find drugs that prevent or treat this problem. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 28, 2020 Category: International Medicine & Public Health Source Type: news

ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)
AstraZeneca to Leverage ArcherDX's PCM Liquid Biopsy Technology to Facilitate Multiple Clinical Trials for Early-Stage Non-Small Cell Lung Cancer Therapies BOULDER, Colo., May 26, 2020 -- (Healthcare Sales & Marketing Network) -- ArcherDX, Inc., today ... Biopharmaceuticals, Diagnostics, Oncology ArcherDX, AstraZeneca, Anchored Multiplex PCR, Personalized Cancer Monitoring (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 26, 2020 Category: Pharmaceuticals Source Type: news

Cancer researchers gain valuable insights through a comprehensive review of Clioquinol
(Bentham Science Publishers) Researchers at Karmanos Cancer Institute of Wayne State University compiled the latest cancer research on clioquinol (CQ), an anti-fungal/anti-protozoal hydroxyquinoline family drug. The authors reported that although CQ isn't suitable for cancer therapy currently, using CQ derivatives or analogues such as nitroxoline as well as combining CQ with other drugs, including docahexaenooic acid or disulfiram, are potential cancer treatments, as supported by strong positive preclinical results. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 21, 2020 Category: Cancer & Oncology Source Type: news

Breast cancer hormone therapy does not increase arthritis risk
According to a Swedish study, anti-hormonal breast cancer therapy does not increase rheumatoid arthritis risk in women, as previously suspected.News Medical (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 14, 2020 Category: Endocrinology Source Type: news

Bristol Myers, bluebird to resubmit cancer therapy filing as FDA declines review
Bristol Myers Squibb Co said on Wednesday it planned to resubmit its application for an experimental multiple myeloma therapy by the end of July after the U.S. drug regulator declined to review the treatment as it sought more information. (Source: Reuters: Health)
Source: Reuters: Health - May 13, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. FDA extends review of Bristol Myers' cancer therapy acquired in Celgene deal
Bristol Myers Squibb said on Wednesday the U.S. drug regulator had extended the review of its experimental blood cancer therapy by three months after the drugmaker submitted additional information to the agency. (Source: Reuters: Health)
Source: Reuters: Health - May 6, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Killing 'sleeper cells' may enhance breast cancer therapy
(Walter and Eliza Hall Institute) The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive (ER+) breast cancer - the most common form of breast cancer in Australia - according to preclinical studies led by Walter and Eliza Hall Institute researchers. The promising preclinical results for this 'triple therapy' have underpinned a phase 1 clinical trial in Melbourne, Australia, that is combining venetoclax with hormone therapy and CDK4/6 inhibitors in patients with ER+ breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 6, 2020 Category: Cancer & Oncology Source Type: news

Nearly a Dozen Approved Drugs Could Be Effective Against COVID-19: Study Nearly a Dozen Approved Drugs Could Be Effective Against COVID-19: Study
At least 10 different drug compounds ranging from cancer therapies to antipsychotics and antihistamines may be effective at preventing the new coronavirus from multiplying in the body, according to a multidisciplinary study conducted by a team of scientists in the United States and France.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 1, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Mathematical Model Predicts Outcomes in Prostate Cancer Therapy
The model was able to use data from each treatment cycle to estimate intratumor subpopulations and accurately predict the outcomes in each subsequent cycle. (Source: CancerNetwork)
Source: CancerNetwork - May 1, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Nearly a dozen approved drugs could be effective against COVID-19: study
At least 10 different drug compounds ranging from cancer therapies to antipsychotics and antihistamines may be effective at preventing the new coronavirus from multiplying in the body, according to a multidisciplinary study conducted by a team of scientists in the United States and France. (Source: Reuters: Health)
Source: Reuters: Health - April 30, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Travel cards could help radiopharma patients avoid delays
Patients who undergo radiation treatment with lutetium-177 DOTATATE for neuroendocrine...Read more on AuntMinnie.comRelated Reading: SNMMI: PSMA-PET helps guide prostate cancer therapy Health Canada OKs AAA's Lutathera agent Novel PET tracer shows promise for neuroendocrine tumors Theranostic approach could aid pancreatic cancer patients SNMMI: PET prostate image lands Image of the Year honors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 29, 2020 Category: Radiology Source Type: news